Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF? activation.
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF? activation. PLoS One. 2012; 7(2):e31384.